Chronic Idiopathic Urticaria (CIU) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Chronic Idiopathic Urticaria (CIU) Market Outlook

Thelansis’s “Chronic Idiopathic Urticaria (CIU) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Idiopathic Urticaria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Idiopathic Urticaria (CIU) Overview

Chronic urticaria (CU) is characterized by recurring hives or welts, which appear at least twice a week for a minimum of 6 weeks. The exact cause of CU is not fully comprehended, but it's believed that the release of histamine due to mast cell degranulation plays a central role. While many CU patients don't have a specific allergen triggering their mast cells, in cases where no underlying cause is identified, the diagnosis is chronic idiopathic urticaria (CIU). CU exhibits various clinical manifestations, primarily marked by the rapid emergence of wheals and angioedema. A wheals typically includes three key elements: (i) a central swelling of variable dimensions, (ii) accompanied by itching or occasionally a burning sensation, and (iii) lasting briefly, usually for 1-24 hours. Angioedema is characterized by sudden, pronounced swelling in the deeper layers of the skin. It can sometimes be painful and takes longer to resolve than wheels (up to 72 hours). Around 40-50% of cases involving urticaria are linked to angioedema. For the management of CIU, treatment follows a stepwise approach as advised by guidelines. Initial steps involve using non-sedating over-the-counter antihistamines. As CIU affects the whole body, topical skin creams are not a suitable treatment option. Omalizumab is the lone FDA-approved biologic treatment for chronic idiopathic/spontaneous urticaria in the United States. I was prescribed for individuals aged 12 and above who continue to experience symptoms despite antihistamine therapy.

• CIU impacts around 1.6 million individuals in the USA and is commonly observed in people aged 20 to 40. Women are twice as likely as men to be affected by CIU.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: